
Dwaipayan Mukherjee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4271710/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 770-781.	2.3	15
2	Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. Biopharmaceutics and Drug Disposition, 2022, 43, 98-107.	1.1	4
3	Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 501-526.	2.3	21
4	Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach. Cancer Chemotherapy and Pharmacology, 2021, 87, 465-474.	1.1	21
5	Physiologicallyâ€Based Pharmacokinetic Models for Evaluating Membrane Transporter MediatedÂDrug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. Clinical Pharmacology and Therapeutics, 2020, 107, 1082-1115.	2.3	88
6	In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities. AAPS PharmSciTech, 2019, 20, 243.	1.5	5
7	Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 443-456.	0.8	17
8	Modeling In Vivo Interactions of Engineered Nanoparticles in the Pulmonary Alveolar Lining Fluid. Nanomaterials, 2015, 5, 1223-1249.	1.9	6
9	Modeling <i>In Vitro</i> Cellular Responses to Silver Nanoparticles. Journal of Toxicology, 2014, 2014, 1-13.	1.4	12
10	Modeling population exposures to silver nanoparticles present in consumer products. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	33
11	Modeling physicochemical interactions affecting in vitro cellular dosimetry of engineered nanomaterials: application to nanosilver. Journal of Nanoparticle Research, 2014, 16, 2616.	0.8	21
12	Physiologically-Based Toxicokinetic Modeling of Zearalenone and Its Metabolites: Application to the Jersey Girl Study. PLoS ONE, 2014, 9, e113632.	1.1	33
13	Computational Multiscale Toxicodynamic Modeling of Silver and Carbon Nanoparticle Effects on Mouse Lung Function. PLoS ONE, 2013, 8, e80917.	1.1	9
14	An Analytical Method for Quantifying Transport and Reaction of Anti-Tumor Drugs in Human Tissues. Journal of Chemical Engineering of Japan, 2009, 42, S226-S233.	0.3	0